Alterity Therapeutics Prices 8.4M Share Placement at A$0.50, Raising A$4.2M
ATHE sits 68% above its 52-week low of $2.66 on light trading volume (0.1× avg).
Summary
Alterity Therapeutics priced an 8.4 million share placement at A$0.50 per share, raising A$4.2 million in working capital under its previously announced MST Financial Services underwriting agreement.
Key Events · Financing and Capital Events · ATHE
-
Placement Priced at A$0.50
8.4 million new ordinary shares issued at A$0.50 each, raising A$4.2 million in gross proceeds for working capital.
-
Underwriting Fee Disclosed
MST Financial Services Pty Ltd will receive a 7% underwriting fee on gross proceeds raised.
-
Post-Issue Share Count
Total quoted ATH ordinary shares on issue following quotation will be 229,100,845.
-
Follows Prior Underwriting Agreement
This filing finalizes the terms of the underwriting agreement announced on 2026-08-31, adding the issue price and fee.
Analysis · ATHE · Life Sciences
The terms of the previously announced underwriting agreement with MST Financial Services have now been finalized, with 8.4 million new ordinary shares priced at A$0.50 each for gross proceeds of A$4.2 million. The underwriter will receive a 7% fee. This capital raise is particularly meaningful given the going-concern language in the FY2026 20-F and a cash position of A$37.3 million, which provides roughly 5.2 quarters of runway. The additional working capital should help extend operations. Notably, the issue price of A$0.50 is below the current ADR-implied price, reflecting the discount typical of a placement to an underwriter.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 29.2% of the 1466 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATHE was trading at $4.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.9M. The 52-week trading range was $2.66 to $5.89. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.